1. The public domain 1.1. The public domain includes the following:
d printed material -leaflets, posters, etc d media -radio, TV, newspapers, magazines, etc d verbal presentations d information on telephone lines and videos d electronic mail d the world wide web 1.2. Information to be provided to the general public 1.2.1. Haematopoietic stem cell donation is used for the treatment of both adult and paediatric patients with various kinds of severe malignant, metabolic and immunologic diseases. Compatibility is primarily based on Human Leucocyte Antigen (HLA) (histocompatibility) identity.
Haematopoietic stem cell donation is:
d Undertaken voluntarily, and withdrawal of the volunteer is permitted at all times d Not remunerated but incurred expenses are met.
(This will be documented within the policy of the responsible Registry and may include loss of earnings.) d Guaranteed to be anonymous for both patient and donor d Health restricted including a requirement that the individual volunteer must not be at high risk of transmittable diseases d Age restricted. The minimum age for a volunteer must be determined by the legal requirement covering general anaesthesia and blood donation in the country in which the donor resides.
The maximum age will be determined by the policy of the responsible Registry. 1.2.3. Registration of a donor implies a general offer to be available for any patient in need of a haematopoietic stem cell transplant anywhere in the world, irrespective of the patient's age, gender, nationality, creed or ethnicity. It should be made clear to volunteers that patients are only eligible for transplant/cell therapy as defined under the WMDA standards. It must be made clear to the volunteer that the Registry will try to trace volunteers who fail to provide updated contact details; legal methods only will be employed by the Registry. 2.1.7. The volunteer has the right to withdraw at any time from the Registry.
Donor consent at time of recruitment
A simple, comprehensible consent form must be signed by the volunteer, which confirms that he/she understands and agrees to the following:
d Join the Registry as a potential haematopoietic stem cell donor and provide relevant samples for HLA typing and IDM testing. It should be made clear to the volunteer that some of the sample material may be stored for an indeterminate period for the purposes of undertaking further HLA typing and IDM testing. While individual Registries may develop their own consent policies, it must be stated that consent to utilise blood samples given voluntarily does not automatically imply consent for the blood samples to be used for purposes other than that to which the volunteer has actively consented. d The principles and risks of haematopoietic stem cell donation, and the implications of transmission of infectious diseases from donor to patient. 
Donor medical evaluation at time of joining Registry
The volunteer must understand that certain diseases in a donor preclude haematopoietic stem cell donation. The volunteer must, at the time of recruitment, complete and sign a medical questionnaire.
Donor samples at time of initial recruitment onto Registry
The volunteer must be advised that blood samples or buccal swabs will be used primarily for histocompatibility testing, blood grouping and IDM testing relevant for the registry file, donor search processes, and haematopoietic stem cell donation and transplantation, and the volunteer must sign a written consent for these purposes. Any use of stored material for purposes other than those related to haematopoietic stem cell donation and transplantation must require an additional and specific written consent from the donor.
Health information to the donor
The Registry and donor centre should have a plan for information to the donors about serious positive IDM results or other abnormal medical findings; this protocol must: (a) identify how each particular donor wishes to receive such information (b) state who has this responsibility, for example, qualified health-care professional (c) provide recommendations of follow-up care.
Confirmatory (final stage) histocompatibility testing
Final stage histocompatibility testing is undertaken by the transplant centre (or associated HLA laboratory) to validate the histocompatibility type of a volunteer donor. At this stage an information session between volunteer and a qualified representative of the donor centre must take place. This may be in person or by telephone. The volunteer must be reminded of all procedures, restrictions and risks involved. Sufficient time should be allowed for the volunteer to ask all questions. The information given must not be coercive. At no time must the volunteer be told that he/she is the only match for a patient.
Donor information at time of confirmatory testing
This information may be given by a trained and qualified health professional (nurse, medical technician, para-medical, etc) who is fully conversant with all aspects of stem cell donation. 3.1.1. Blood samples taken at this stage are sent to the appropriate transplant centre or associated laboratory, where they are subject to histocompatibility testing, testing for infectious disease markers and other relevant analyses. 3.1.2. Haematopoietic stem cell harvesting will be undertaken by bone marrow aspiration under anaesthesia (spinal or general), or, if it is a part of the registry's programme, by peripheral blood stem cell (PBSC) collection following G-CSF mobilisation.
The side effects and risks associated with the procedures must be discussed with the volunteer. In particular, the volunteer should also be informed about all aspects of G-CSF administration, including possible short-and long-term effects that are known or questioned at the time of information.
As a preference for PBSC may be expressed by the transplant centre, the volunteer will be asked to consider both forms of donation. However, he/she does not have to make a decision at this stage. 3.1.3. Final stage confirmatory testing has determined the volunteer's likely selection as a donor. Repeat samples are sometimes required at this stage. 3.1.4. The current probability of being selected to donate to a specific patient. 3.1.5. The likely time frame within which the volunteer will hear if he/she is a match. The responsible Registries should fulfil their commitments to the volunteer by ensuring he/she receives the results within 100 days. 3.1.6. The location of the collection centre in which the procedure would be undertaken. It should be made clear that travel to another country is not necessary. 3.1.7. The potential time commitment involved in either of the donation procedures and subsequent recovery period. 3.1.8. Volunteer retains the right to withdraw at any stage. 3.1.9. A medical examination is necessary to assess the volunteer's fitness for the donation procedure. The responsible physician will be independent of any association with the transplant patient. 3.1.10. Volunteers are not remunerated for donation;
however, out-of-pocket expenses will be refunded and loss of earnings may be claimed. If compensation for expenses and/or loss of earning cannot be offered, an explanation should be given to the volunteer at this stage. 3.1.11. The probability for the treatment to be successful for the patient. General terms should be used.
3.1.12. Following initial haematopoietic stem cell donation, the possibility of further donation requests for the same patient should be discussed briefly.
Donor consent at time of confirmatory testing
All the foregoing information should also be contained in an information sheet and the volunteer should sign a consent form confirming that he/she has read, understood and agrees to all the above procedures. In the event of a volunteer being unable to read, the information must be communicated to him/her as appropriate. In countries where more than one language is used, the information should be provided in the language that is most readily understood by the volunteer donor.
Donor medical evaluation at time of confirmatory testing
A further medical questionnaire must be completed by the volunteer at the time of final stage confirmatory testing. This updates and supplements the data provided at the time of initial recruitment and/or at additional typing. The updated medical information should identify any volunteers whose current medical condition now precludes them from donating, in the best interests of either the volunteer or the patient.
Health information to the donor
The Registry and donor centre should have a plan for information to the donors about serious positive IDM results and/or medical findings; this protocol must: (a) identify how each particular donor wishes to receive such information (b) state who has this responsibility, for example, qualified health-care professional (c) provide recommendations of follow-up care.
Haematopoietic Stem Cell Donation

Consultation before the harvest
This information should be given by a trained and qualified medical doctor, at least during the main information session. 4.1.1. At the time of obtaining consent from definitive selection of a donor for harvest, an extensive information session -ideally face to face -with a responsible and qualified member of the donor or harvest centre must take place. This may be preceded by a preliminary telephone conversation. 4.1.2. Sufficient time and a relaxed environment should be available for detailed discussions with the volunteer. 4.1.3. The volunteer should be able to invite a person of their choice to be present at the information session held prior to formally consenting to donate. 4.1.4. The volunteer must have the opportunity and be encouraged to ask all questions he/she feels necessary, and detailed, accurate, noncoercive answers given. 4.1.5. The volunteer should be offered the opportunity to talk to one or more volunteers who have already donated. Where possible, volunteers with similar lifestyles, backgrounds, and commitments as the donor should be identified, as this will enable the potential donor to have further insight into the experience he/she will undergo both during and postdonation.
It is the responsibility of the donor centre to ensure that volunteers selected to talk to potential donors in this way have a balanced view of the experience and that ample time is provided for the donor to consider the donation. 4.1.6. A donor advocate should be available to discuss the approaching donation with the volunteer. The advocate must be an independent third party who is not a member of the Registry, harvest, donor or transplant centre; the advocate must be conversant with haematopoietic stem cell donation. The role of the advocate is to provide independent support, assist the volunteer in fully understanding the procedure and enable the volunteer to reach his/her decision. It must be made clear that the donor advocate bears no legal or financial responsibility for the donor. 4.1.7. The information session should be conducted with the aid of a comprehensive checklist to ensure that all aspects have been covered. The check-list should be signed by the person conducting the information session and countersigned by the volunteer. A copy must be provided to the donor.
Information to be covered at the above consultation.
The volunteer must be informed/reminded of the following: d He/she is considered a match for a particular patient and is now requested to donate haematopoietic stem cells. d The type of haematopoietic stem cell collection available, that is, bone marrow or PBSC. A comprehensive overview, readily understood by a lay person, of both collection procedures (marrow/PBSC), with their respective advantages and disadvantages for the donor. d The risks of the procedures: (a) Bone marrow -anaesthesia and associated morbidity, infection and possible damage to bone, nerves or tissues at the aspiration sites, transfusion reactions. (b) PBSC -expected reactions to administration of growth factors including possible adverse reactions (including known and debated short and long term effects); possible use of a central venous line for apheresis and associated risks with this procedure, infection, increased risk of bruising and bleeding, nerve injury and thrombosis. Long-term safety of growth factors is unknown. d The requirement for collection of autologous blood unit(s) and associated risks. d The possible need for allogeneic blood units and associated risks. d The probability in general terms for successful treatment of the patient.
d The extent of the insurance coverage which will be taken out on behalf of the volunteer. The volunteer is advised to ensure that this coverage does not affect any of his/her existing policies. d The purpose of the medical examination prior to donation. The volunteer may also wish to consult his/her own physician. d The short-term after-effects of either procedure and their likely recovery time postdonation. The donor must be made aware that the procedure may be debilitating requiring, in a small percentage of cases, a longer recovery period. d Volunteers are not remunerated for donation;
however, out-of-pocket expenses will be refunded and, in some cases, loss of earnings might be claimed.
(Policy of responsible Registry will apply) d The possibility of postponement/cancellation through changes in the medical condition of the patient. d The continuing contact the donor centre will maintain with the volunteer to monitor post donation recovery. d That established standards will be maintained respecting both donor and recipient confidentiality. d With his/her subsequent consent, he/she may be asked whether he/she is willing to make further donations (haematopoietic stem cells or other supportive cell therapy) for the same patient. It must be stressed that the volunteer would only be approached with the approval of the Medical Director of the Registry and/or donor centre. The volunteer retains the right to decline.
Donor consent prior to haematopoietic stem cell collection
The wording of the consent form will vary according to the legal requirements of the country of domicile. However, it is recommended that the consent form confirms the following:
4.3.1. The volunteer has discussed, with a suitably qualified person, the collection procedures permissible, and understands the related risks. (Including anaesthesia, transfusion reaction, infection, bone, nerve or other tissue damage at the needle insertion site and the possibility of short-and long-term adverse effects of haematopoietic growth factors.) 4.3.2. The donation method elected by the volunteer. 4.3.3. All information has been given in a clear and understandable manner and opportunity provided to ask questions and have these answered fully and satisfactorily. 4.3.4. The volunteer's right to withdraw consent and the volunteer's understanding of the consequences for the patient if he/she withdraws consent after the transplant protocol has commenced. 4.3.5. The haematopoietic stem cells will be received by an anonymous recipient. The patient must remain anonymous permanently if the patient elects this or if it is the policy of the responsible Registry. The patient's identity may only be provided to the donor if the patient requests and it is the Registry and transplant centre's policy to allow patientdonor contact. for use in research relevant to haematopoietic stem cell donation. The donor has to give informed consent every time blood is drawn for research purposes.
Post donation
If a donor is no longer medically eligible to continue, the subject of further donations must not be addressed. Similarly, if a donor wishes to decline from any further commitment, this must be respected and the subject of future donations may not be broached. In both cases, the transplant centre should be advised that the donor is no longer available, and the volunteer must be deleted from the active donor panel of the Registry.
For those volunteers still eligible and wishing to remain on the donor Registry, the following must be considered. This should be commenced once the donor has recovered initially from haematopoietic stem cell donation but should be completed during the early follow-up period and within 4 weeks of primary donation:
5.1. The volunteer must be reminded that he/she may be approached for a further donation (haematopoietic stem cell or other cell therapy) for the same patient and, where possible, given an indication of any timescale(s). 5.2. Comprehensive information should be made available to the volunteer on why, in order to assist with patient recovery, further donations may be required. 5.3. An explanation of all possible methods of collection must be provided at this time and may be written or verbal. 5.4. The volunteer should be asked to consider seriously their willingness, in principle, to be approached for further donation for the same patient. 5.5. The volunteer must be allowed to determine which, if any, procedures he/she will consider. 5.6. Following haematopoietic stem cell donation, the volunteer must be asked of his/her willingness to remain on the Registry with a view to being approached for further donations to other patients.
(WMDA guidelines or Registry policy will determine the frequency with which a donor may be approached again). a To be used in conjunction with the paper on Informed Consent, in particular points 4.1-4.3.7 inclusive.
